In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Immunome Inc (NASDAQ: IMNM) closed the day trading at $20.82 down -3.07% from the previous closing price of $21.48. In other words, the price has decreased by -$3.07 from its previous closing price. On the day, 2.11 million shares were traded. IMNM stock price reached its highest trading level at $21.5 during the session, while it also had its lowest trading level at $20.21.
Ratios:
For a better understanding of IMNM, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.90 and its Current Ratio is at 8.90. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In the most recent recommendation for this company, Truist on December 01, 2025, initiated with a Buy rating and assigned the stock a target price of $36.
On September 22, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $26.
On September 05, 2025, Craig Hallum started tracking the stock assigning a Buy rating and target price of $26.Craig Hallum initiated its Buy rating on September 05, 2025, with a $26 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 30 ’25 when SIEGALL CLAY B bought 4,729 shares for $21.15 per share. The transaction valued at 100,018 led to the insider holds 665,254 shares of the business.
Barchas Isaac sold 383,200 shares of IMNM for $8,330,080 on Dec 22 ’25. The Director now owns 2,031,181 shares after completing the transaction at $21.74 per share. On Dec 19 ’25, another insider, SIEGALL CLAY B, who serves as the President and CEO of the company, bought 7,278 shares for $20.48 each. As a result, the insider paid 149,053 and bolstered with 860,525 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMNM now has a Market Capitalization of 2297180416 and an Enterprise Value of 1640781952. For the stock, the TTM Price-to-Sale (P/S) ratio is 237.31 while its Price-to-Book (P/B) ratio in mrq is 7.23. Its current Enterprise Value per Revenue stands at 169.52 whereas that against EBITDA is -8.021.
Stock Price History:
The Beta on a monthly basis for IMNM is 2.23, which has changed by 0.85892856 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, IMNM has reached a high of $25.30, while it has fallen to a 52-week low of $5.15. The 50-Day Moving Average of the stock is 12.11%, while the 200-Day Moving Average is calculated to be 76.62%.
Shares Statistics:
Over the past 3-months, IMNM traded about 1.86M shares per day on average, while over the past 10 days, IMNM traded about 2602640 shares per day. A total of 110.33M shares are outstanding, with a floating share count of 99.36M. Insiders hold about 9.94% of the company’s shares, while institutions hold 80.18% stake in the company. Shares short for IMNM as of 1765756800 were 15876802 with a Short Ratio of 8.53, compared to 1763078400 on 14324512. Therefore, it implies a Short% of Shares Outstanding of 15876802 and a Short% of Float of 18.040001.
Earnings Estimates
The dynamic stock of Immunome Inc (IMNM) is currently attracting attention from 11.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.46 and low estimates of -$0.64.
Analysts are recommending an EPS of between -$1.87 and -$2.41 for the fiscal current year, implying an average EPS of -$2.2. EPS for the following year is -$2.56, with 11.0 analysts recommending between -$1.92 and -$3.52.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for IMNM’s current fiscal year. The highest revenue estimate was $11M, while the lowest revenue estimate was $6.9M, resulting in an average revenue estimate of $7.77M. In the same quarter a year ago, actual revenue was $9.04M
